Patents by Inventor Philip Ng

Philip Ng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060023549
    Abstract: Fuse data used to configure ancillary circuits used with a non-volatile serial memory core are stored in locations within the memory core. As a first opcode or word is sent on a serial bus to the memory, a logic circuit intercepts the word and generates read fuse enable pulses that fetch the fuse data and configure the ancillary circuits before the last bit of the first command byte arrives. If a read operation is designated, the memory circuits are configured to read. If a write operation is designated, further fuse data is fetched from the memory core to configure ancillary circuits for writing. The fuse data is written to the memory core at the time of circuit manufacture thereby obviating the need for separate storage locations.
    Type: Application
    Filed: August 2, 2004
    Publication date: February 2, 2006
    Inventors: Jinshu Son, Liqi Wang, Minh Le, Philip Ng
  • Publication number: 20050140419
    Abstract: An auto-grounding circuit responsive to a reset signal discharges an input terminal of an integrated circuit and its associated input line to ground, using a pull-down transistor coupled to the input line, with a gate of the pull-down transistor coupled to receive the reset signal. An exemplary circuit also includes a NAND gate and a second pull-down transistor to maintain an established voltage level of the input line after the reset signal is no longer asserted until the input terminal is driven by an applied input signal. The voltage maintaining circuitry is weaker than the main pull-down transistor to avoid interfering with normal operation of the input terminal.
    Type: Application
    Filed: December 31, 2003
    Publication date: June 30, 2005
    Inventors: Philip Ng, Jeff Tsai, Johnny Chan
  • Publication number: 20050115683
    Abstract: An improved Roman blind assembly is disclosed. The Roman blind assembly consists of a fabric screen mounted to a pair of suspension cords and a pair of pull cords. Each of the suspension cords consists of an elongated flexible cord having a plurality of loops formed along a length of the cord, each loop being a loop of flexible cord defining a loop opening. The blind assembly also includes a plurality of elongated mounting elements mounted to the fabric screen to form a plurality of parallel folds, each of said mounting element being mounted to one of the loops of each suspension cord. Finally, the blind assembly also includes a drawing mechanism for pulling up the fabric screen by drawing up the pull cords.
    Type: Application
    Filed: November 29, 2004
    Publication date: June 2, 2005
    Inventors: Philip Ng, Xiulian Zhang, Norman Wills
  • Publication number: 20050086440
    Abstract: An integrated circuit device includes a plurality of non-volatile memory cells associated with a plurality of flag cells storing managing data. The managing data of the flag cells forms a data set. The data set is utilized to determine to which memory cell of the plurality of memory cells to write new data and from which of the memory cells to read currently stored data. The data set is changed to a different data set whenever a new value is written to a designated memory cell to indicate an alternate memory cell to be written to next and an alternate memory cell to be read from next. The data set may be changed by alternately writing a new value to a different flag cell in each successive change of the data set.
    Type: Application
    Filed: October 20, 2003
    Publication date: April 21, 2005
    Inventors: Johnny Chan, Philip Ng, Tinwai Wong
  • Patent number: 6855534
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA, at least one head-to-head ITR junction, and recombinase recognition sites positioned such that site-specific recombination between recombinase recognition sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express a site-specific recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: February 15, 2005
    Inventors: Frank L. Graham, Robin Parks, Philip Ng
  • Publication number: 20050031068
    Abstract: A shift register device includes transistor pass gates and latches connected in series and disposed along a data bit line, each latch connected to a corresponding transistor pass gate. Each transistor pass gate is controlled by a separate control signal input line that a provides a signal to the transistor pass gate connected to it. The signals are provided in a staggered time pattern beginning with a latch disposed last in succession, shifting data from one position to the next succeeding position. Each latch is capable of storing one bit of data. The shift register utilizes less silicon space while reducing the amount of power consumed during operation.
    Type: Application
    Filed: August 4, 2003
    Publication date: February 10, 2005
    Inventors: Johnny Chan, Jeff Tsai, Philip Ng
  • Publication number: 20040142470
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA and lox sites positioned such that site-specific recombination between lox sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express the Cre recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof. Use of recombinases besides Cre and recombinase recognition sites besides lox sites, and use of cells other than 293 cells are also disclosed and enabled, as are kits incorporating the site-specific vector system.
    Type: Application
    Filed: July 19, 2001
    Publication date: July 22, 2004
    Inventors: Frank L. Graham, Robin Parks, Philip Ng
  • Patent number: 6756226
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA, at least one head-to-head ITR junction, and optionally, recombinase recognition sites positioned such that site-specific recombination between recombinase recognition sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express a site-specific recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: June 29, 2004
    Inventors: Frank L. Graham, Robin Parks, Philip Ng
  • Publication number: 20030228280
    Abstract: The present invention relates to methods for efficient and reliable construction of adenovirus vectors which contain and express foreign DNA and are useful for gene transfer into mammalian cells, for vaccines and for gene therapy. The invention provides for the growth and purification of adenovirus vectors (helper dependent vectors or HDVs) from which all or most of the viral genes have been removed. The vector system described herein is a new method designed to eliminate helper viruses from the final HDV preparation by cleavage of the helper virus DNA with an endonuclease, alone or in combination with other methods known to limit the level of helper virus contamination of helper dependent vector preparations. The disclosed methods and compositions also provide for regulated control of gene expression.
    Type: Application
    Filed: January 31, 2003
    Publication date: December 11, 2003
    Inventors: Frank L. Graham, Philip Ng, Robin Parks, Silvia Bacchetti, Mauro Anglana
  • Publication number: 20030165463
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA, at least one head-to-head ITR junction, and recombinase recognition sites positioned such that site-specific recombination between recombinase recognition sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express a site-specific recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof.
    Type: Application
    Filed: October 16, 2001
    Publication date: September 4, 2003
    Inventors: Frank L. Graham, Robin Parks, Philip Ng
  • Publication number: 20020168341
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA, at least one head-to-head ITR junction, and optionally, recombinase recognition sites positioned such that site-specific recombination between recombinase recognition sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express a site-specific recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof.
    Type: Application
    Filed: October 16, 2001
    Publication date: November 14, 2002
    Inventors: Frank L. Graham, Robin Parks, Philip Ng
  • Publication number: 20020136708
    Abstract: The present invention relates to methods for efficient and reliable construction of adenovirus vectors which contain and express foreign DNA and are useful for gene transfer into mammalian cells, for vaccines and for gene therapy. The invention provides for the growth and purification of adenovirus vectors (helper dependent vectors or HDVs) from which all or most of the viral genes have been removed. The vector system described herein is a new method designed to eliminate helper viruses from the final HDV preparation by cleavage of the helper virus DNA with an endonuclease, alone or in combination with other methods known to limit the level of helper virus contamination of helper dependent vector preparations. The disclosed methods and compositions also provide for regulated control of gene expression.
    Type: Application
    Filed: June 19, 2001
    Publication date: September 26, 2002
    Inventors: Frank L. Graham, Philip Ng, Robin Parks, Silvia Bacchetti, Mauro Anglana
  • Patent number: 6379943
    Abstract: In the present invention, viruses, plasmids or both are constructed which contain viral DNA and lox sites positioned such that site-specific recombination between lox sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express the Cre recombinase. Because of the high-efficiency and specificity of the Cre enzyme, suitably engineered plasmids can be readily recombined to produce infectious virus at high-efficiency in cotransfected 293 cells, without, at the same time, producing wild-type adenovirus, with the attendant problems for removal thereof. Use of recombinases besides Cre and recombinase recognition sites besides lox sites, and use of cells other than 293 cells are also disclosed and enabled, as are kits incorporating the site-specific vector system, as well as compositions and methods for using such compositions as vaccines or in gene therapeutic applications.
    Type: Grant
    Filed: March 5, 1999
    Date of Patent: April 30, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Frank L. Graham, Robin J. Parks, Philip Ng